Despite advances in therapeutic regimens, local failure in lung cancer continues to be a problem for radiation therapy (1 -3) . Currently, the most common approach to improve the outcome of radiotherapy is to combine radiation with chemotherapeutic agents (4 -8) . However, many of the platinum-based chemotherapeutic agents used as standard treatment for lung cancer exhibit toxicity within normal tissues (9 -13) . Therefore, the development of nontoxic, yet effective molecular-targeted radiosensitizers is essential for improvement of the therapeutic ratio.
Understanding the response of the tumor microenvironment to ionizing radiation is important for the development of efficient radiosensitizing agents (14 -16) . Previous data have shown that the effectiveness of radiotherapy is limited by the response of the tumor vasculature (16, 17) . Several studies have shown that clinically relevant doses of ionizing radiation (2-5 Gy) elicit the activation of both Akt and extracellular signal-regulated kinase 1/2 (ERK1/2) prosurvival signaling pathways in tumor endothelium (17 -20) . The result of such activation is increased radioresistance within the tumor blood vessels. Because ablation of the tumor vasculature enhances the treatment of cancer (21, 22) , radiosensitizers that target these survival pathways could improve the outcome of lung cancer. Upon irradiation, signal transduction is generated during the interaction of ionizing radiation with cellular membranes (23, 24) . Our recent study showed that ionizing radiation interacts with vascular endothelial cell membranes to produce a biologically active lysophospholipid. In response to 3 Gy, human umbilical vein endothelial cells exhibited immediate activation of cytosolic phospholipase A2 (cPLA 2 ; ref. 17) . cPLA 2 belongs to a superfamily of enzymes that specifically cleave the acyl ester bond of membrane phospholipids at the sn-2 position (25 -28) . As a result of this hydrolysis, both free fatty acid and lysophospholipids are generated. Radiation-induced activation of cPLA 2 in vascular endothelial cells resulted in the increased production of lysophosphatidylcholine, a lipidderived second messenger which triggered Akt and ERK1/2 phosphorylation (17) . Lysophosphatidylcholine activates a wide range of cell types within the vascular system and can regulate a variety of biological functions including cytokine synthesis, migration, and endothelial growth factor expression (29, 30) . According to our data and others, lysophosphatidylcholine could induce signal transduction through the transactivation of vascular endothelial growth factor receptor 2 (Flk-1/KDR). The result of this signaling cascade is an increase in endothelial cell proliferation and survival (17, 29) . Such data suggest that cPLA 2 may play a critical role in the tumor vascular response to ionizing radiation and could be used as a molecular target for tumor radiosensitization.
In previous studies, much of the data were generated using normal vascular endothelial cells. However, the genes expressed by tumor endothelial cells differ significantly from the genes expressed by human umbilical vein endothelial cells and human microvascular endothelial cells. In order to analyze the efficacy of cPLA 2 inhibitors as radiosensitizers in vitro, we selected endothelial cells that are considered to be more clinically relevant to malignant disease (31) . To test the hypothesis that cPLA 2 inhibition promotes the radiosensitization of tumor blood vessels, we used the 3B11 murine vascular endothelial cell line as well as murine pulmonary microvascular endothelial cells (MPMEC) isolated directly from mouse lung tissue.
To inhibit cPLA 2 , we used arachidonyltrifluoromethyl ketone (AACOCF 3 ). This potent cPLA 2 inhibitor is a cell-permeable trifluoromethyl ketone analog of arachidonic acid (25) . Nuclear magnetic resonance studies have shown that the carbon chain of AACOCF 3 binds in a hydrophobic pocket of cPLA 2 and the carbonyl group of AACOCF 3 forms a covalent bond with serine 228 in the enzyme active site (25, 32, 33) . This cPLA 2 inhibitor has been used extensively to study the role of cPLA 2 in platelet aggregation and inflammation-associated apoptosis (34 -37) . In the present study, however, we utilized AACOCF 3 to elucidate the role of cPLA 2 in the tumor vasculature response to ionizing radiation. We found that when combined with radiation, the inhibition of cPLA 2 with AACOCF 3 disrupts the biological functions of the tumor vasculature, enhances destruction of tumor blood vessels, and suppresses tumor growth. Thus, cPLA 2 contributes to vascular endothelial cell radioresistance and presents a potential molecular target for tumor sensitization to radiotherapy.
Materials and Methods
Cell cultures and treatment. The murine endothelial cell line 3B11 was purchased from the American Type Culture Collection. 3B11 cells were maintained in DMEM plus 10% fetal bovine serum and 1% penicillin/streptomycin (Life Technologies) in a 37jC and 5% CO 2 environment. MPMEC were maintained in EGM-2-MV (Cambrex). Cells from passages 2 to 3 were used in this study. Mouse Lewis Lung Carcinoma (LLC) and human large cell lung cancer H460 cells were obtained from the American Type Culture Collection. The LLC cell line was maintained in DMEM supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin; H460 cells were cultured in RPMI 1640 (Life Technologies) supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin. AACOCF 3 was purchased from EMD Biosciences. Cells were pretreated with either vehicle (70% EtOH) or 1 Amol/L AACOCF 3 (in 70% EtOH) for 30 min prior to irradiation (3 Gy). A Mark I 137 Cs irradiator (J.L. Shepherd and Associates) was used to deliver radiation to the cells.
Mouse tumor models, treatment and tumor growth delay study. Institutional Animal Care and Use Committee (IACUC) guidelines were followed when handling and treating all mice used in this study (IACUC-approved protocols M/04/013 and M/07/358). 10 6 of LLC or H460 cells were implanted into the hind limbs of C57/BL6 mice and nude mice, respectively. Once tumors exceeded 2 mm in diameter, the mice were stratified into groups of 5 to 6 animals representing similar distributions of tumor sizes. Tumor-bearing animals were administered i.p. with vehicle or 10 mg/kg AACOCF 3 30 min prior to irradiation with 3 Gy (Therapax DXT 300 X-ray machine; Pantak Inc.). Treatment was repeated for 5 consecutive days. Tumor size was monitored by external caliper measurements.
Isolation of mouse lung endothelial cells. Primary cultures of MPMEC were isolated as described previously (38) . Briefly, 1-to 3-month-old C57/BL6 mice were anesthetized, and the lung vasculature was perfused with PBS and 2 mmol/L EDTA followed by 0.25% trypsin and 2 mmol/L EDTA via the right ventricle. The heart and lungs were excised and incubated at 37jC for 20 min. The visceral pleura was removed, and the perfusion was repeated. Primary vascular endothelial cells were recovered and grown on tissue culture plates coated with 0.2% gelatin for 3 d in EGM-2-MV containing 5% FCS (Cambrex).
Clonogenic survival. The 3B11, LLC, and H460 cells were plated and allowed to attach for 5 h. Cells were then treated with EtOH or 1 Amol/L AACOCF 3 for 30 min followed by irradiation with 0, 2, 4, or 6 Gy. Medium was changed after irradiation. After 1 wk, plates were fixed with 70% EtOH and stained with 1% methylene blue. Colonies consisting of z50 cells were counted with a dissection microscope. Average survival fraction was calculated as (number of colonies/number of cells plated)/(number of colonies for corresponding control/number of cells plated) with SE from three experiments.
Western immunoblot analysis. Total cell lysates from 3B11, LLC, and H460 were harvested 3 min after the beginning of irradiation. Total protein extraction was done using M-PER kit (Pierce). Protein concentration was quantified using BCA Reagent (Pierce). Protein extracts (80 Ag) were subjected to Western immunoblot analysis using antibodies for the detection of phospho-ERK1/2 Thr202/Tyr204 and total ERK1/2 (both from Cell Signaling Technologies). Antibody to actin (j) was used to evaluate protein loading in each lane. Immunoblots were
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developed using the Western Lightning Chemiluminescence Plus detection system (PerkinElmer) according to the manufacturer's protocol.
Matrigel-based tubule formation assay. In order to analyze capillarylike formation, 24-well plates were coated with Matrigel (300 AL per well; BD Biosciences) and incubated for 30 min at 37jC. Primary MPMEC or 3B11 cells were plated over solidified Matrigel and allowed to attach for 30 min prior to treatment. Cells were then treated with vehicle or 1 Amol/L AACOCF 3 for 30 min and irradiated with 3 Gy. Once tubules began to form from the control cells, digital microphotographs of the wells were obtained. Four randomly selected high power fields (HPF) per sample were counted, and tubule formation was quantified as the average number of tubule branches per HPF.
Endothelial cell migration assay. To assay cell migration, 3B11 or MPMEC were added to the top chamber of 24-well plates (100,000 cells/well) with 8 Am matrigel-coated inserts (Costar Corning). Fresh medium (600 AL) was added to the bottom chamber, and cells were incubated for 30 min to allow attachment. Both chambers were then treated with vehicle or 1 Amol/L AACOCF 3 for 30 min prior to irradiation (3 Gy). Cells were incubated for 24 h at 37jC in 5% CO 2 . After 24 h, all remaining cells on the upper surface of the transwell insert filter were removed with a cotton swab. The insert filters were rinsed in PBS, fixed in 100% methanol, and stained with 4 ¶,6-diamidino-2-phenylindole (DAPI; 2.5 ng/AL). Migrated cells in 6 randomly selected HPF from each sample were counted, and the average number of migrated cells per HPF was calculated.
Power doppler sonography analyses of tumor blood flow. C57/BL6 mice bearing LLC tumors received daily i.p. injections with vehicle or 10 mg/kg AACOCF 3 . Tumors were irradiated with 3 Gy 30 min after inhibition. Treatment was repeated for 5 consecutive days. Twenty-four hours after the final treatment, tumor blood flow was analyzed by three-dimensional Power Doppler Sonography. Tumors were sonographically imaged with a VisualSonics VEVO 770 small animal high resolution ultrasound scanner equipped with a 40 MHz transducer and a mechanically scanned, single-element aperture (VisualSonics). The focal zone of the transducer was set at 6 mm from the scanning surface. The scanning plane was perpendicular to the long axis of the lower extremity along the entire length of the tumor. Three-dimensional images in Power Doppler mode were acquired by computer-controlled translation of the transducer over the whole length of the tumor by acquiring two-dimensional images every 100 Am. The following ultrasound scanner settings were used: Power Doppler transmission frequency-23 MHz, Power Gain 100%, wall filter 2.3 mm/s, scan speed 2.0 mm/s. Three-dimensional tumor volume was reconstructed using semiautomated segmentation of 10 to 12 parallel planes through the two-dimensional images using the VisualSonics image analysis software. To determine blood flow, the average vascular index (%) was calculated as the ratio of color coded pixels (representing blood flow) to the total pixel volume of the tumor.
Histologic analysis of tumor vascularity. Tumor-bearing mice were treated with daily i.p. injections of vehicle or 10 mg/kg AACOCF 3 30 min prior to irradiation with 3 Gy. Treatment was continued for 5 consecutive days. Twenty-four hours after the final treatment, tumors were resected, fixed in 10% formalin, and sectioned into 5-Am sections. Sections were incubated with 20 Ag/mL Proteinase K for antigen retrieval and then hybridized overnight with rabbit antihuman von Willebrand Factor (vWF) antibody (1:100; DakoCytomation). Sections were subsequently incubated with Alexa Fluor 488-conjugated goat antirabbit antibody (1:500; Invitrogen Molecular Probes) for 1 h at room temperature before imaging. Positive staining was observed by immunofluorescent microscopy, and vessels were counted (6 randomly selected HPF per sample). Vascularity was determined as the average number of stained vessels per HPF.
TUNEL staining and immunofluorescence staining for phospho-Akt. Mice bearing LLC tumors received daily i.p. injections of vehicle or 10 mg/kg AACOCF 3 30 min prior to irradiation with 3 Gy. Treatment was continued for 5 consecutive days. Twenty-four hours after the final treatment, tumors were harvested, fixed in 10% formalin, and sectioned into 5-Am sections. Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining was done with the DeadEnd Colorimetric TUNEL System (Promega) following the manufacturer's instructions. Positive staining was observed by light microscopy. To detect Akt phosphorylation, sections were incubated with 20 Ag/mL Proteinase K for antigen retrieval and then hybridized overnight at 4jC with antibodies for phospho-Akt Thr308/Ser473 (1:100; Cell Signaling Technologies). Sections were subsequently incubated with Alexa Fluor 488-conjugated goat antirabbit antibody (1:500; Invitrogen Molecular Probes) for 1 h at room temperature. Counterstaining was done using DAPI (2.5 ng/AL), and positive staining was observed by immunofluorescence microscopy.
Tumor vascular window model and vascular length density analysis. The tumor window model experiment was described previously (39) . Briefly, LLC tumor cells were injected into the dorsal skinfold of C57/BL6 mice. After approximately 2 wk, sufficient vascular networks had developed within all of the mice. Mice were then treated with AACOCF 3 , 3 Gy, or AACOCF 3 plus 3 Gy. Prior to treatment, the window frame was marked with coordinates, which were used to photograph the same microscopic field each day. Blood vessel appearance was monitored at 24-h increments over a period of 120 h. Once the study was complete, color photographs were scanned into Photoshop and analyzed using ImagePro software. Within this software, vascular center lines were positioned along the entire length of the blood vessels. Vascular length density was then calculated by the software as total pixilation of blood vessel length per area of tissue.
Statistical analysis. Statistical tests were carried out using SigmaPlot 8.0 data analysis software. Data are presented as group means F SE. An unpaired Student's t test was used to evaluate the significance of the differences between two sets of data. A calculated P < 0.05 was considered statistically significant.
Results
Inhibition of cPLA 2 with AACOCF 3 enhances cell death and prevents activation of prosurvival signaling in irradiated vascular endothelial cells. To determine whether treatment with AACOCF 3 affects cellular viability in irradiated tumor cells as well as vascular endothelial cells, we did clonogenic survival assays for 3B11, LLC, and H460 cell lines. The studies showed that treatment with AACOCF 3 enhances radiation-induced cell death among 3B11 vascular endothelial cells (Fig. 1A) . The most pronounced statistically significant increase in radiosensitization was observed at 2 Gy. At this dose, 3B11 cells exhibited a 30% decrease in survival in comparison with irradiated cells treated with vehicle alone (Fig. 1A and B) . Treatment with AACOCF 3 did not result in radiosensitization of LLC or H460 (Fig. 1A and B) .
Our previous studies have shown that in irradiated human umbilical vein endothelial cells, activation of cPLA 2 regulates ERK1/2 phosphorylation, one of the radiation-induced prosurvival kinases (17) . To investigate whether the effects of AACOCF 3 on 3B11 cell viability are due to the similar changes in radiation-induced prosurvival signaling, we did Western immunoblot analysis for ERK1/2 phosphorylation using total cell lysates of all three tested cell lines (Fig. 1C) . At 3 minutes postirradiation, AACOCF 3 prevented the radiation-induced phosphorylation of ERK1/2 in vascular endothelial cells, but not in LLC or H460 tumor cells (Fig. 1C) . This suggests that in response to radiation, differential radiation-induced cPLA 2 Shown are bar graphs of the average tubule formation for 3B11 (A) and MPMEC (B) with SE from three independent experiments; *, P < 0.05. Migration assay is shown. 3B11cells (C) or MPMEC cells (D) were added to the top chamber of 24-well plates with 8-Am matrigel-coated inserts. Fresh medium was added to the bottom chamber, and both chambers were treated with vehicle (control) or 1 Amol/L AACOCF 3 for 30 min prior to irradiation with 3 Gy. After 24 h, the insert chambers were stained with DAPI and migrated cells were counted (6 HPF per sample). Shown are representative micrographs of migrated 3B11taken 24 h after treatment (C) and bar graphs of the average number of migrated cells per HPF for 3B11 (C) and MPMEC (D) with SE from three independent experiments; *, P < 0.05. Fig. 2A ). However, a combined treatment of AACOCF 3 followed by irradiation significantly decreased tubule formation as compared with control cells (29 versus 53; Fig. 2A) . A similar response was observed in MPMEC, in which treatment with AACOCF 3 prior to irradiation reduced the average number of tubules formed per HPF by 50% when compared with control cells (Fig. 2B) .
Inhibition of cPLA 2 results in decreased migration in irradiated vascular endothelial cells. To determine whether cPLA 2 inhibition affects the migratory ability of vascular endothelial cells, 3B11 or MPMEC were treated with vehicle or 1 Amol/L AACOCF 3 for 30 minutes prior to irradiation. Migration was assessed by a transwell filter migration assay. In the 3B11 cell line, no significant reduction in migration was observed in cells treated with either radiation or AACOCF 3 alone (Fig. 2C) . In contrast, treatment with AACOCF 3 prior to irradiation reduced migration by 39% in comparison with cells treated with vehicle alone (62 versus 112; Fig. 2C ). MPMEC produced comparable results in which treatment with AACOCF 3 prior to irradiation significantly attenuated the number of migrated cells per HPF (11 versus 63; Fig. 2D ).
Inhibition of cPLA 2 represses tumor growth in irradiated mouse models. To determine the efficacy of cPLA 2 inhibition in vivo, both syngeneic and heterogeneic mouse lung tumor models were used. Mouse LLC or human H460 tumor cells were injected s.c. into the right hindlimbs of 6-week-old male C57/ BL6 or nude mice, respectively. Tumor-bearing mice received daily i.p. injections of vehicle or 10 mg/kg AACOCF 3 30 minutes prior to irradiation. Treatment was repeated for 5 consecutive days and tumor volume was determined by external caliper measurements. In the LLC model, treatment with either radiation or drug alone failed to produce a significant delay in tumor growth (2.6 days versus 1.8 days, respectively; Fig. 3A and B) . Mice treated with a combined treatment of AACOCF 3 and radiation, however, produced a statistically significant tumor growth delay of 12.2 days ( Fig. 3A and B; P < 0.05). In the H460 tumor mouse model, inhibition of tumor growth was not observed in mice treated with AACOCF 3 alone (Fig. 3C) . Treatment with radiation resulted in a tumor growth delay of 5.5 days, but maximum tumor growth inhibition of 12.3 days was observed in mice treated with AACOCF 3 plus radiation (Fig. 3D) . Figure 3C illustrates the differences in H460 tumor volumes among treatment groups 13 days postinjection. Although radiation resulted in decreased tumor size compared with untreated mice (950 mm 3 versus 1447 mm 3 ; Fig. 3C ), a combined treatment of AACOCF 3 and radiation enhanced tumor growth suppression by an additional 40% (567 mm 3 ; Fig. 3C ). cPLA 2 inhibition attenuates tumor blood flow and decreases vascularity in irradiated tumors. To determine if the cPLA 2 inhibitor AACOCF 3 impedes tumor blood flow, mice bearing LLC tumors were treated once daily for 5 consecutive days with either vehicle or 10 mg/kg AACOCF 3 for 30 minutes followed by irradiation with 3 Gy. Tumor blood flow was analyzed by three-dimensional Power Doppler Sonography. As shown in 1640 Fig. 4A and B, the average vascular indices were 12% and 15% for untreated and irradiated tumors, respectively. Treatment with AACOCF 3 resulted in a 1.6-fold decrease in tumor vascular index as compared with untreated mice (7.5% versus 12%; Fig. 4B ). This decrease in tumor vasculature was further potentiated in mice that received a combined treatment of AACOCF 3 and radiation (2-fold, 6% versus 12%; Fig. 4B ).
To investigate whether inhibition of cPLA 2 using AACOCF 3 affects tumor vascularity, tumor-bearing mice were treated with daily i.p. injections of vehicle or 10 mg/kg AACOCF 3 30 minutes prior to irradiation with 3 Gy. Treatment was continued for 5 consecutive days. Twenty-four hours after the final treatment, tumors were resected, fixed, and sectioned into 5-Am sections. Sections were then stained with anti-vWF antibody. Staining was assessed by immunofluorescent microscopy. Figure 4C and D illustrate the effects of cPLA 2 inhibition on vascularity within irradiated tumors. Radiation alone produced a slight reduction in vascularity in comparison with untreated mice (6% versus 10%; Fig. 4D ). In addition, treatment with AACOCF 3 resulted in a significant decrease in total blood vessel number (4%; Fig. 4D ). The most pronounced reduction in overall vascularity, however, was observed in mice treated with AACOCF 3 followed by radiation (2%; Fig. 4D ).
Treatment with AACOCF 3 results in apoptosis and inhibition of Akt phosphorylation within irradiated tumors. To determine the effects of AACOCF 3 on cellular viability in vivo, we did TUNEL staining on LLC tumor sections from treated mice and analyzed the sections for the presence of apoptosis (Fig. 5A) . In tumor sections from untreated mice or mice treated with radiation alone, we did not find TUNEL-positive cells. Mice treated with the inhibitor alone exhibited TUNEL-positive staining within a small population of cells. The most pronounced effect was detected in tumors from mice treated with a combination of AACOCF 3 and irradiation. Within these tumors, we observed a significant increase in apoptosis of the endothelial cells lining the tumor blood vessels (Fig. 5A, black arrows) . The results also revealed elevated TUNEL-positive staining among those tumor cells located in close proximity to the blood vessels (Fig. 5A, red  arrows) .
To determine whether AACOCF 3 affects radiation-induced prosurvival signaling within irradiated tumors, we did immunofluorescence staining for phospho-Akt on tumor sections from LLC-bearing mice (Fig. 5B) . In tumors from untreated mice or mice treated with 3 Gy, we observed increased levels of Akt phosphorylation. In comparison, treatment with drug alone resulted in decreased phospho-Akt levels throughout the entire tumor. Inhibition of Akt phosphorylation was further potentiated in tumors from mice that received a combined treatment of 10 mg/kg AACOCF 3 followed by irradiation with 3 Gy.
Tumor vascular window model and vascular length density analysis. To investigate the effects of cPLA 2 inhibition on tumor vasculature radiosensitivity, we used a dorsal skinfold window model. LLC cells were implanted into the dorsal skinfold window in C57/BL6 mice, and a sufficient vascular network was allowed to develop. Vascular windows were then treated with the cPLA 2 inhibitor AACOCF 3 30 minutes prior to irradiation with 3 Gy. At 72 hours posttreatment, the average percent vascular length densities were 71% and 42% for mice treated with drug alone or irradiation, respectively (Fig. 6) . A combined treatment of AACOCF 3 and radiation, however, resulted in statistically significant destruction of tumor blood vessels (26%; Fig. 6 ). These radiosensitization effects persisted at 96 hours posttreatment, in which vascular length density was further reduced by AACOCF 3 followed by irradiation (13%; Fig. 6B ).
Discussion
In the tumor vascular endothelium, clinically relevant low doses of radiation trigger the activation of prosurvival signaling pathways. This results in enhanced radioresistance of tumor vasculature that can significantly diminish overall cancer treatment success rates. Thus, pharmacologic agents and therapeutic strategies that confer radiosensitivity to tumor blood vessels could improve tumor control. cPLA 2 is a key component in the response of vascular endothelial cells to ionizing radiation. Radiation-induced activation of cPLA 2 leads to the downstream phosphorylation of the prosurvival targets Akt and ERK1/2 (17) . In our present study, we provide evidence that chemical inhibition of cPLA 2 with AACOCF 3 can increase the radiation-induced destruction of tumor blood vessels and may significantly improve the response of radioresistant lung tumors to radiation therapy.
Using a syngeneic lung tumor model of LLC, we showed that a combined treatment of AACOCF 3 and radiation inhibited tumor growth by 75% as compared with untreated tumors. To further verify the role of cPLA 2 in tumor growth progression, we used a xenograft lung tumor model of H460 cells. Treatment with AACOCF 3 plus radiation resulted in tumor growth suppression similar to that of the LLC tumor model. However, because H460 cells are more radiosensitive than LLC, the increase in radiosensitization from the combined treatment was not as pronounced. Therefore, these findings suggest that cPLA 2 is a relevant molecular target for lung tumors that are highly resistant to radiation therapy.
Another strategy to evaluate the efficacy of cPLA 2 inhibition in vivo is to quantitatively measure the effects on tumor blood flow (40) . In the current study, we used Power Doppler Sonography to provide a noninvasive assessment of the efficacy of this antivascular therapy. This strategy is supported by prior studies of inhibition of molecular targets in the vascular endothelium (41, 42) . We showed that cPLA 2 inhibition with AACOCF 3 reduced tumor blood flow in irradiated tumors. Thus, these data support the hypothesis that cPLA 2 inhibition combined with radiation leads to a disruption of tumor blood vessel function. To assess whether the overall tumor blood vessel number was affected by cPLA 2 inhibition, we used vWF as a marker for vascularity. vWF is a glycoprotein that mediates platelet adhesion to sites of vascular injury, and is a well-accepted immunohistochemical marker of endothelial cells (43 -45) . Our study revealed that tumors from mice treated with AACOCF 3 followed by radiation exhibited a significant reduction in blood vessel number. Upon further immunohistochemical analysis, we found that this attenuation of blood flow and reduction in overall vascularity is associated with the induction of apoptosis within tumor vascular endothelial cells. In addition, immunofluorescence staining revealed that treatment with AACOCF 3 followed by 3 Gy suppresses radiation-induced Akt phosphorylation in irradiated tumors. This observation along with increased apoptosis in tumor cells and tumor vasculature suggests the possibility of multiple mechanisms involved in the radiosensitizing effects of the cPLA 2 inhibitor AACOCF 3 . Thus, future investigation of the host-tumor interaction may provide clarification of the molecular events responsible for the increased efficacy of cPLA 2 inhibition in irradiated cancer.
The tumor vascular window model allows direct measurement of the vascular response to ionizing radiation in vivo (39). Our results revealed that, in the absence of irradiation, AACOCF 3 alone had no significant effect on existing vasculature. When treated with AACOCF 3 followed by radiation, however, enhanced destruction of tumor blood vessels was observed. Taken together, these data showed that in irradiated mouse tumor models, AACOCF 3 disrupts the biological functions of the tumor vasculature, enhances destruction of tumor blood vessels, and suppresses tumor growth. Therefore, the cPLA 2 inhibitor AACOCF 3 is an effective radiosensitizer in mouse lung tumor models.
To provide further in vitro validation for our therapeutic strategy, we investigated the effects of cPLA 2 inhibition in the 3B11 cell line as well as in primary vascular endothelial cells isolated directly from lung tissue. In selecting the appropriate cell-based models for the preclinical development of radiosensitizers, it is ideal to identify a murine vascular endothelial cell line that maintains the expression of traditional endothelial cell markers as well as markers found to be expressed by human tumor endothelial cells (31) . 3B11 is a murine vascular endothelial cell line that expresses the mouse homologs for five tumor endothelial markers: mTEM1, mTEM3, mTEM5, mTEM7, and mTEM8. Like normal endothelial cells, 3B11 also expresses many of the murine homologs of standard endothelial cell markers, including sialomucin/CD34, GPIIIB/CD36, and VCAMI/CD106 (31). Thus, 3B11 has been identified as a relevant murine model for tumor vascular endothelial cells (31, 46, 47) . In addition, we also used primary pulmonary vascular endothelial cells, the closest physiologic cell culture model for lung cancer vasculature. Our cell culture experiments showed that cPLA 2 inhibition with AACOCF 3 followed by radiation prevented radiation-induced activation of prosurvival signaling (ERK1/2) and significantly enhanced cell death. This effect was observed in vascular endothelial cells but not in lung tumor cell lines. This differential response suggests a fundamental regulatory role for radiation-induced cPLA 2 -dependent activation of prosurvival signal transduction pathways in the viability of irradiated vascular endothelial cells as compared with tumor cells. Additional functional assays revealed that treatment with AACOCF 3 reduced migration and attenuated tubule formation in irradiated 3B11 and primary vascular endothelial cells. Taken together, these data indicate that cPLA 2 inhibition confers radiosensitivity to tumor vasculature and may disrupt tumor blood vessel function.
These findings identify cPLA 2 as a critical component of the tumor vascular response to ionizing radiation. In the present study, we found that cPLA 2 inhibition prevents the formation of a functional tumor vascular network both in vivo and in cell culture, disrupts already formed tumor blood vessels, and significantly delays tumor growth. Thus, cPLA 2 inhibition with AACOCF 3 enhances the radiation-induced destruction of tumor vasculature and may significantly improve lung tumor response to radiation therapy. . Tumor vascular window model and vascular length density analysis. LLC cells were implanted into the dorsal skinfold window in C57/BL6 mice. A sufficient vascular network was allowed to develop, and windows were treated with AACOCF 3 30 min prior to irradiation with 3 Gy. Color photographs were taken daily to monitor blood vessel appearance. A, representative micrographs of 40Â magnification of LLC tumor vascular window models at 0 h and 72 h after treatment. B, changes in the quantity of blood vessels over time were compared with that observed at 0 h. Shown is a bar graph of the percent vascular length density 72 and 96 h after treatment of implanted tumors with SE from group of 3 to 5 mice; *, P < 0.05. cPLA 2 in Radiosensitization of Tumor Vasculature
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